| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/09/2006 | US7041674 nortropane or nortropene derivatives; antagonists of the M3 receptor for treating asthma, COPD, vagally induced sinus bradycardia, arrhythmia, gastrointestinal and urinary tract spasms, and menstrual pain |
| 05/09/2006 | US7041673 Ultrashort acting hypnotic barbiturates |
| 05/09/2006 | US7041672 Substituted aryl 1, 4-pyrazine derivatives |
| 05/09/2006 | US7041671 N-(1-ethylpropyl)- or N-(1-methylpropyl)-7-(6-methoxy-2-methylpyridin-3-yl)-2,6-dimethylpyrrolo[1,2-b]pyridazin-4-amine or their salts, used for treating disorders manifesting hypersecretion of CRF receptors, such as anxiety, and depression. |
| 05/09/2006 | US7041670 Florfenicol-type antibiotics |
| 05/09/2006 | US7041669 1,4-benzofused urea compounds useful in treating cytokine mediated diseases |
| 05/09/2006 | US7041668 Substituted benzimidazole compounds and their use for the treatment of cancer |
| 05/09/2006 | US7041667 CCR5 modulators |
| 05/09/2006 | US7041666 Adenosine A2a receptor antagonists |
| 05/09/2006 | US7041665 Central nervous system disorders; anxiolytic agents; antidepressants; antiepilepsy agents; antiarthritic agents |
| 05/09/2006 | US7041664 e.g., (S)-N-(1-phenylpropyl)-2-(pyrrolidin-1-yl)-quinoline-4-carboxamide in a container with instructions for treating anxiety, depression, schizophrenia, obesity, chronic pulmonary obstructive disorder, or pain |
| 05/09/2006 | US7041663 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| 05/09/2006 | US7041662 Substituted benzo [b] azepin-2-one compounds |
| 05/09/2006 | US7041661 Use of thiazolobenzoheterocycles for treating multiple sclerosis |
| 05/09/2006 | US7041660 2-[2-[3-(2-Guanidinoacetylamino)pyrrolidin-1-ylcarbonyl]-1-methylpyrrolidin-4-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylic acid 3 hydrate ethanol; thienamycins; storage stability, shelf life |
| 05/09/2006 | US7041659 Compounds for the treatment of metabolic disorders |
| 05/09/2006 | US7041658 topically administering a neutral endopeptidase inhibitor that is an N-aminocarbonylmethyl-substituted phosphonamide or phosphoramide |
| 05/09/2006 | US7041657 Topical semi-crystalline beta-1,4-n-acetylglucosamine polymers free of proteins and contaminants; stimulating endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel |
| 05/09/2006 | US7041656 Sulfated fucoglucuronomannan |
| 05/09/2006 | US7041655 hydroxyethyl starch or dextran and superoxide dismutase, glutathione peroxidase, catalase, hydroxyethyl rutoside, cyclic adenosine monophosphate or vitamin C; prevents the harmful effect of free radicals on cellular membranes and other organelles during a period of increased capillary permeability |
| 05/09/2006 | US7041654 Treating or preventing cancer by administering to subject a vector comprising a heterologous polynucleotide operably linked to one or more regulatory sequences derived from an H19, IGF-1 or IGF-2 P4 transcriptional regulatory sequence |
| 05/09/2006 | US7041653 Gene transcription and ionizing radiation: methods and compositions |
| 05/09/2006 | US7041652 administering ascorbic acid, ascorbate or a derivative thereof in combination with quercetin-3-O-glucoside (isoquercetin), quercetin-4'-glucoside, quercetin-3'-glucoside, or quercetin-7-glucoside to increase bioavailability |
| 05/09/2006 | US7041651 Cellular uptake of bioactive agents |
| 05/09/2006 | US7041650 Anticonvulsant derivative salts |
| 05/09/2006 | US7041640 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| 05/09/2006 | US7041638 Surfactant prevention of vaginitis and lung complications from cancer chemotherapy |
| 05/09/2006 | US7041461 Nucleotide sequences coding membrame protein for use in analgesics |
| 05/09/2006 | US7041322 Phloridzin-rich phenolic fraction and use thereof as a cosmetic, dietary or nutraceutical agent |
| 05/09/2006 | US7041321 supercritically extracting an herb to obtain an oil extract and a residue;extracting the residue in a water/alcohol liquid mixture to obtain a post-supercritical hydroalcoholic extract; evaporating the water/alcohol liquid to form a powdered extract; mixing the powdered extract with the oil extract. |
| 05/09/2006 | US7041319 Fenofibrate pharmaceutical composition having high bioavailabilty |
| 05/09/2006 | US7041318 Fluid energy milling a crystalline material using a milling fluid comprising helium at reduced temperature; crystalline triamcinolone acetonide for inhalation, for example |
| 05/09/2006 | US7041317 Sustained-release preparation containing 5-acetyl-4,6-dimethyl-2[2-[4-(2-methoxyphenyl) piperazinyl]ethylamino] pyrimidine trihydrochloride as active ingredient |
| 05/09/2006 | US7041316 Stable oral pharmaceutical dosage forms |
| 05/09/2006 | US7041314 GPE analogs and peptidominetics |
| 05/09/2006 | US7041313 e.g., pantoprazole; combination of one administration form that is the drug with a disintegrant and a sustained-release coating of a water-insoluble and plastic membrane with low swelling power in water and in which small soluble particles are embedded and other form is the drug with an enteric coating |
| 05/09/2006 | US7041312 Wound healing compositions and methods of use |
| 05/09/2006 | US7041311 Preparation for saliva flow |
| 05/09/2006 | US7041309 Spinal fusion using an HMG-CoA reductase inhibitor |
| 05/09/2006 | US7041305 Stable water in oil aminophylline emulsions |
| 05/09/2006 | US7041303 Use of moxonidine for postmyocardial infarction treatment |
| 05/09/2006 | US7041291 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 05/09/2006 | US7041286 aspirin, magnesium, and nattokinase, and either niacin or nitroglycerine, especially in the form of a chewable tablet, nasal spray, or suppository |
| 05/09/2006 | US7041281 Maleic compound modified aplha-olefin |
| 05/09/2006 | US7041280 Aryl boronate functionalized polymers for treating obesity |
| 05/09/2006 | US7041275 Irrigating fluid |
| 05/09/2006 | US7041241 Microspheres contain 5-fluorouracil coated with poly(d-l-lactic acid-co-glycolic acid); implanted in walls of operation site following exeresis of tumor, by intratissular injection |
| 05/09/2006 | US7041175 Method for the continuous production of hydrolytically broken down and possibly substituted starch, use of hydrolytically broken down starch and device for producing same |
| 05/09/2006 | US7041063 Noninvasive measurement of chemical substances |
| 05/09/2006 | US7040314 Aerosol generating devices and methods for generating aerosols suitable for forming propellant-free aerosols |
| 05/09/2006 | US7040311 Closure-cap and container as a two-chamber cartridge for nebulizers for producing aerosols and active substance formulations, suitable for storage |
| 05/09/2006 | CA2418908C 1,4-dihydropyridines as bradykinin antagonists |
| 05/09/2006 | CA2395653C New inhalable powder containing tiotropium |
| 05/09/2006 | CA2388431C Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment |
| 05/09/2006 | CA2346662C Compositions containing diphosphonic acids |
| 05/09/2006 | CA2322501C Processes for the preparation of (r)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
| 05/09/2006 | CA2322341C Highly resistant granular starch |
| 05/09/2006 | CA2262668C Inhibitors of cathepsin k |
| 05/09/2006 | CA2257646C Benzo[g]quinoline derivatives |
| 05/09/2006 | CA2257328C Thiazole derivatives |
| 05/09/2006 | CA2245588C Polysaccharide precipitation process |
| 05/09/2006 | CA2239489C 3-pyrazolecarboxamide derivatives having cannabinoid receptor affinity |
| 05/09/2006 | CA2238430C Pyrazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives |
| 05/09/2006 | CA2233716C Methods of using discodermolide compounds |
| 05/09/2006 | CA2205745C Method for the preparation of baccatin iii and derivatives thereof from 10-deacetylbaccatin iii |
| 05/09/2006 | CA2205573C Enterokinetic benzamide |
| 05/09/2006 | CA2175687C A bacterial nitroreductase gene-prodrug system |
| 05/09/2006 | CA2173506C Enteric granule-containing tablets |
| 05/09/2006 | CA2141652C Fluorinated vitamin d3 derivative |
| 05/09/2006 | CA2125105C Substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic and medicament containing them |
| 05/08/2006 | CA2497031A1 Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals |
| 05/05/2006 | CA2511320A1 Insulin-like growth factor-1 secretagogue |
| 05/04/2006 | WO2006047756A2 Substituted tetracycline compounds |
| 05/04/2006 | WO2006047755A2 Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (hit) syndrome |
| 05/04/2006 | WO2006047744A2 Compositions of lactoferrin related peptides and uses thereof |
| 05/04/2006 | WO2006047738A2 Dosage forms having a microreliefed surface and methods and apparatus for their production |
| 05/04/2006 | WO2006047716A2 Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus associated disease |
| 05/04/2006 | WO2006047702A2 Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds |
| 05/04/2006 | WO2006047692A2 Dosage forms having a microreliefed surface and methods and apparatus for their production |
| 05/04/2006 | WO2006047671A2 4-aminotetracyclines and methods of use thereof |
| 05/04/2006 | WO2006047661A2 Phosphonate derivatives of mycophenolic acid |
| 05/04/2006 | WO2006047631A2 Anti-mitotic anti-proliferative compounds |
| 05/04/2006 | WO2006047590A2 Compositions and treatments of bacterial vaginosis |
| 05/04/2006 | WO2006047579A2 Vitamin e tpgs fluid concentrate comprising a low percentage of water |
| 05/04/2006 | WO2006047574A1 (2-carboxamido)(3-amino) thiophene compounds |
| 05/04/2006 | WO2006047557A2 Compositions and methods of dispensing palliative or therapeutic agents |
| 05/04/2006 | WO2006047556A2 Methods for making and using synergistic multifunctional compositions |
| 05/04/2006 | WO2006047544A2 Compositions and methods for treating alzheimer’s disease and related disorders and promoting a healthy nervous system |
| 05/04/2006 | WO2006047537A1 Certain compounds, compositions, and methods |
| 05/04/2006 | WO2006047528A2 Pyrazolobenzamides and derivatives as factor xa inhibitors |
| 05/04/2006 | WO2006047522A1 Hypoestoxides, derivatives, agonists and crude extracts thereof for use in topical compositions |
| 05/04/2006 | WO2006047516A2 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| 05/04/2006 | WO2006047514A2 Daph analogs and inhibition of protein aggregation |
| 05/04/2006 | WO2006047507A2 Phosphonate substituted kinase inhibitors |
| 05/04/2006 | WO2006047504A1 Aromatic amides as inhibitors of c-fms kinase |
| 05/04/2006 | WO2006047503A2 Inhibitors of c-fms kinase |
| 05/04/2006 | WO2006047492A2 Substituted nitrogen-containing heterocycles as vanilloid receptor ligands and their uses as medicament |
| 05/04/2006 | WO2006047479A2 C-fms kinase inhibitors |
| 05/04/2006 | WO2006047477A1 Compositions for treating and/or preventing diseases characterized by the presence of the metal ions |
| 05/04/2006 | WO2006047476A2 Therapeutic and delivery methods of prostaglandin ep4 agonists |